AI Financial Corporation (NasdaqCM: AIFC)
Financials · Capital Markets · US
$0.64
-5.02% today · -89.7% 1Y
AI Financial Corporation (NasdaqCM: AIFC) operates in the Capital Markets industry within the Financials sector. The company is valued at $94.52M and employs 16 people.
Over the last twelve months the share price has lost 89.7%, trading between 0.36 and 8.74.
Tweenvest scores AI Financial Corporation across four factors: quality 36/100, value 65/100. Its strongest factor is value.
AIFC price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $94.52M
- Revenue (TTM)
- $20.74M
- P/E
- —
- EPS
- -7.21
- Dividend yield
- —
- Beta (5Y)
- 1.81
- 52-week high
- $8.74
- 52-week low
- $0.36
- Avg volume (3M)
- —
- Shares outstanding
- 139.84M
- Employees
- 16
- Next earnings
- —
About AI Financial Corporation
AI Financial Corporation, a global entity operating through its various subsidiaries, specializes in distributed ledger technology solutions. The company's activities are strategically divided into two primary segments: Fintech and Biotechnology. Its Fintech division manages the entire ecosystem of digital assets, covering everything from their initial creation (tokenization) to their trading, clearing, settlement, payment processing, and secure safekeeping. Within this sector, AI Financial offers significant products such as ALT 5 Prime, a sophisticated electronic over-the-counter (OTC) trading platform designed for the acquisition and divestiture of digital assets. Another key offering is ALT 5 Pay, a cryptocurrency payment gateway that empowers merchants to either accept and disburse payments in digital currencies directly or integrate this capability into their existing software applications. The biotechnology arm is dedicated to identifying, procuring, licensing, advancing, collaborating on, and commercializing innovative, non-opioid, and non-addictive therapeutic solutions for addressing pain and addiction. Noteworthy projects include JAN 101, an orally administered, sustained-release sodium nitrite compound that has successfully concluded Phase 2a clinical trials for the treatment of peripheral arterial disease and pain. Additionally, the company is developing JAN123, a low-dose naltrexone formulation specifically tailored for managing chronic regional pain syndrome. Established in 1976, the company is based in Las Vegas, Nevada. It officially adopted its current name, AI Financial Corporation, in April 2026, having previously been known as ALT5 Sigma Corporation.
- ISIN
- US47089W1045
- Founded
- 1976
- Listed since
- Nov 7, 1991
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Capital Markets companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Vanguard Index Funds - Vanguard Morningstar Total Stock Market ETFARCA: VTI | $2.31T | $378.15 | +0.29% |
| Vanguard Index Funds - Vanguard S&P 500 ETFARCA: VOO | $1.67T | $704.02 | +0.31% |
| iShares Trust - iShares Core S&P 500 ETFARCA: IVV | $892.30B | $769.62 | +0.32% |
| State Street SPDR S&P 500 ETF TrustARCA: SPY | $811.28B | $765.91 | +0.32% |
| Invesco QQQ Trust, Series 1NasdaqGM: QQQ | $483.79B | $710.72 | +0.62% |
| Vanguard Index Funds - Vanguard Morningstar Growth ETFARCA: VUG | $377.81B | $87.40 | +0.54% |
| Morgan StanleyNYSE: MS | $340.45B | $216.78 | +0.00% |
| The Goldman Sachs Group, Inc.NYSE: GS | $320.59B | $1,061.00 | +0.20% |
Figures last refreshed Aug 18, 2026.